1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Dermatological OTC Drugs Market Size Growth Rate by Type: 2017 VS 2021 VS 2028
1.2.2 Acne Medications
1.2.3 Dermatitis Drugs
1.2.4 Fungal Infection Drugs
1.3 Market by Distribution Channel
1.3.1 Global Dermatological OTC Drugs Market Share by Distribution Channel: 2017 VS 2021 VS 2028
1.3.2 Online Distribution
1.3.3 Offline Distribution
1.4 Study Objectives
1.5 Years Considered
2 Global Growth Trends
2.1 Global Dermatological OTC Drugs Market Perspective (2017-2028)
2.2 Dermatological OTC Drugs Growth Trends by Region
2.2.1 Dermatological OTC Drugs Market Size by Region: 2017 VS 2021 VS 2028
2.2.2 Dermatological OTC Drugs Historic Market Size by Region (2017-2022)
2.2.3 Dermatological OTC Drugs Forecasted Market Size by Region (2023-2028)
2.3 Dermatological OTC Drugs Market Dynamics
2.3.1 Dermatological OTC Drugs Industry Trends
2.3.2 Dermatological OTC Drugs Market Drivers
2.3.3 Dermatological OTC Drugs Market Challenges
2.3.4 Dermatological OTC Drugs Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Dermatological OTC Drugs Players by Revenue
3.1.1 Global Top Dermatological OTC Drugs Players by Revenue (2017-2022)
3.1.2 Global Dermatological OTC Drugs Revenue Market Share by Players (2017-2022)
3.2 Global Dermatological OTC Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Dermatological OTC Drugs Revenue
3.4 Global Dermatological OTC Drugs Market Concentration Ratio
3.4.1 Global Dermatological OTC Drugs Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Dermatological OTC Drugs Revenue in 2021
3.5 Dermatological OTC Drugs Key Players Head office and Area Served
3.6 Key Players Dermatological OTC Drugs Product Solution and Service
3.7 Date of Enter into Dermatological OTC Drugs Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Dermatological OTC Drugs Breakdown Data by Type
4.1 Global Dermatological OTC Drugs Historic Market Size by Type (2017-2022)
4.2 Global Dermatological OTC Drugs Forecasted Market Size by Type (2023-2028)
5 Dermatological OTC Drugs Breakdown Data by Distribution Channel
5.1 Global Dermatological OTC Drugs Historic Market Size by Distribution Channel (2017-2022)
5.2 Global Dermatological OTC Drugs Forecasted Market Size by Distribution Channel (2023-2028)
6 North America
6.1 North America Dermatological OTC Drugs Market Size (2017-2028)
6.2 North America Dermatological OTC Drugs Market Size by Country (2017-2022)
6.3 North America Dermatological OTC Drugs Market Size by Country (2023-2028)
6.4 United States
6.5 Canada
7 Europe
7.1 Europe Dermatological OTC Drugs Market Size (2017-2028)
7.2 Europe Dermatological OTC Drugs Market Size by Country (2017-2022)
7.3 Europe Dermatological OTC Drugs Market Size by Country (2023-2028)
7.4 Germany
7.5 France
7.6 U.K.
7.7 Italy
7.8 Russia
7.9 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Dermatological OTC Drugs Market Size (2017-2028)
8.2 Asia-Pacific Dermatological OTC Drugs Market Size by Country (2017-2022)
8.3 Asia-Pacific Dermatological OTC Drugs Market Size by Country (2023-2028)
8.4 China
8.5 Japan
8.6 South Korea
8.7 Southeast Asia
8.8 India
8.9 Australia
9 Latin America
9.1 Latin America Dermatological OTC Drugs Market Size (2017-2028)
9.2 Latin America Dermatological OTC Drugs Market Size by Country (2017-2022)
9.3 Latin America Dermatological OTC Drugs Market Size by Country (2023-2028)
9.4 Mexico
9.5 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Dermatological OTC Drugs Market Size (2017-2028)
10.2 Middle East & Africa Dermatological OTC Drugs Market Size by Country (2017-2022)
10.3 Middle East & Africa Dermatological OTC Drugs Market Size by Country (2023-2028)
10.4 Turkey
10.5 Saudi Arabia
10.6 UAE
11 Key Players Profiles
11.1 Perrigo Company plc
11.1.1 Perrigo Company plc Company Detail
11.1.2 Perrigo Company plc Business Overview
11.1.3 Perrigo Company plc Dermatological OTC Drugs Introduction
11.1.4 Perrigo Company plc Revenue in Dermatological OTC Drugs Business (2017-2022)
11.1.5 Perrigo Company plc Recent Development
11.2 Bausch Health Companies Inc.
11.2.1 Bausch Health Companies Inc. Company Detail
11.2.2 Bausch Health Companies Inc. Business Overview
11.2.3 Bausch Health Companies Inc. Dermatological OTC Drugs Introduction
11.2.4 Bausch Health Companies Inc. Revenue in Dermatological OTC Drugs Business (2017-2022)
11.2.5 Bausch Health Companies Inc. Recent Development
11.3 Dr. Reddy's Laboratories
11.3.1 Dr. Reddy's Laboratories Company Detail
11.3.2 Dr. Reddy's Laboratories Business Overview
11.3.3 Dr. Reddy's Laboratories Dermatological OTC Drugs Introduction
11.3.4 Dr. Reddy's Laboratories Revenue in Dermatological OTC Drugs Business (2017-2022)
11.3.5 Dr. Reddy's Laboratories Recent Development
11.4 Johnson and Johnson
11.4.1 Johnson and Johnson Company Detail
11.4.2 Johnson and Johnson Business Overview
11.4.3 Johnson and Johnson Dermatological OTC Drugs Introduction
11.4.4 Johnson and Johnson Revenue in Dermatological OTC Drugs Business (2017-2022)
11.4.5 Johnson and Johnson Recent Development
11.5 Bayer AG
11.5.1 Bayer AG Company Detail
11.5.2 Bayer AG Business Overview
11.5.3 Bayer AG Dermatological OTC Drugs Introduction
11.5.4 Bayer AG Revenue in Dermatological OTC Drugs Business (2017-2022)
11.5.5 Bayer AG Recent Development
11.6 GlaxoSmithKline plc.
11.6.1 GlaxoSmithKline plc. Company Detail
11.6.2 GlaxoSmithKline plc. Business Overview
11.6.3 GlaxoSmithKline plc. Dermatological OTC Drugs Introduction
11.6.4 GlaxoSmithKline plc. Revenue in Dermatological OTC Drugs Business (2017-2022)
11.6.5 GlaxoSmithKline plc. Recent Development
11.7 Viatris Inc
11.7.1 Viatris Inc Company Detail
11.7.2 Viatris Inc Business Overview
11.7.3 Viatris Inc Dermatological OTC Drugs Introduction
11.7.4 Viatris Inc Revenue in Dermatological OTC Drugs Business (2017-2022)
11.7.5 Viatris Inc Recent Development
11.8 LEO Pharma A/S
11.8.1 LEO Pharma A/S Company Detail
11.8.2 LEO Pharma A/S Business Overview
11.8.3 LEO Pharma A/S Dermatological OTC Drugs Introduction
11.8.4 LEO Pharma A/S Revenue in Dermatological OTC Drugs Business (2017-2022)
11.8.5 LEO Pharma A/S Recent Development
11.9 Acella Pharmaceuticals, LLC
11.9.1 Acella Pharmaceuticals, LLC Company Detail
11.9.2 Acella Pharmaceuticals, LLC Business Overview
11.9.3 Acella Pharmaceuticals, LLC Dermatological OTC Drugs Introduction
11.9.4 Acella Pharmaceuticals, LLC Revenue in Dermatological OTC Drugs Business (2017-2022)
11.9.5 Acella Pharmaceuticals, LLC Recent Development
11.10 Teva Pharmaceutical Industries Ltd.
11.10.1 Teva Pharmaceutical Industries Ltd. Company Detail
11.10.2 Teva Pharmaceutical Industries Ltd. Business Overview
11.10.3 Teva Pharmaceutical Industries Ltd. Dermatological OTC Drugs Introduction
11.10.4 Teva Pharmaceutical Industries Ltd. Revenue in Dermatological OTC Drugs Business (2017-2022)
11.10.5 Teva Pharmaceutical Industries Ltd. Recent Development
11.11 Galderma
11.11.1 Galderma Company Detail
11.11.2 Galderma Business Overview
11.11.3 Galderma Dermatological OTC Drugs Introduction
11.11.4 Galderma Revenue in Dermatological OTC Drugs Business (2017-2022)
11.11.5 Galderma Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
